home > drugs a-z list > zyflo cr (zileuton extended release tablets) drug center > zyflo cr (zileuton extended release tablets) drug - overdosage and contraindications

Human experience of acute overdose with zileuton is limited. A patient in a clinical study took between 6.6 and 9.0 grams of zileuton immediate-release tablets in a single dose. Vomiting was induced and the patient recovered without sequelae. Zileuton is not removed by dialysis. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted as required. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. A Certified Poison Control Center should be consulted for up-to-date information on management of overdose with ZYFLO CR.

The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively). In dogs, at an oral dose of 1000 mg/kg (providing in excess of 12 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose) no deaths occurred but nephritis was reported.

The use of ZYFLO CR is contraindicated in patients with:

• Active liver disease or persistent hepatic function enzyme elevations greater than or equal to 3 times the upper limit of normal ( > 3xULN) [see WARNINGS AND PRECAUTIONS, and Use In Specific Populations].
• A history of allergic reaction to zileuton or any of the ingredients of ZYFLO CR (e.g., rash, eosinophilia, etc.).

Last reviewed on RxList: 12/12/2011
This monograph has been modified to include the generic and brand name in many instances.